Mirati Therapeutics, Inc. – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Financials Filter

ended 09/30/23 Q3

ended 06/30/23 Q2

ended 03/31/23 Q1

ended 12/31/22 FY 2022

ended 09/30/22 Q3

Prospectuses and Registrations Filter

Securities registration termination

Removal from listing

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Ownership Filter

Armistice Capital, LLC

Baker Bros. Advisors LP

Avoro Capital Advisors LLC

Rtw Investments, LP

Vanguard Group Inc

News Filter

Contingent Value Rights Agreement

Shareholder Vote Results

Receives Positive Opinion From CHMP for KRAZATI (Adagrasib) as a Targeted Treatment Option for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With a KRASG12C Mutation Following a Re-Examination Procedure

Proxies Filter

Additional info about upcoming vote

Additional info about upcoming vote

Additional info about upcoming vote

Proxy related to merger

Preliminary proxy related to merger

Other Filter

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness

Scanned paper annual report submission

Confidential treatment order